1.	Record Nr.	UNINA9910865258403321
	Autore	Sharma Kavita
	Titolo	Artificial Intelligence in Drug Development : Patenting and Regulatory Aspects / / by Kavita Sharma, Padmavati Manchikanti
	Pubbl/distr/stampa	Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2024
	ISBN	981-9729-54-8
	Edizione	[1st ed. 2024.]
	Descrizione fisica	1 online resource (159 pages)
	Collana	Frontiers of Artificial Intelligence, Ethics and Multidisciplinary Applications, , 2731-8133
	Altri autori (Persone)	ManchikantiPadmavati
	Disciplina	343.099
	Soggetti	Information technology - Law and legislation Mass media - Law and legislation Health services administration Artificial intelligence IT Law, Media Law, Intellectual Property Health Care Management Artificial Intelligence
	Lingua di pubblicazione	Inglese
	Formato	Materiale a stampa
	Livello bibliografico	Monografia
	Nota di contenuto	Artificial Intelligence in Drug Development - Nature and Scope -- Analysis of AI Related Patents in the Healthcare -- Regulation of AI in Drug Development -- Policy and Regulation for AI for Indian Drug and Healthcare Industry -- Way forward for Patenting and Regulation in relation to AI.
	Sommario/riassunto	This book discusses how Artificial Intelligence developments have revolutionized the area of medicine and how companies use them to develop applications. While the book covers the growth of AI in medicine and the early developments in AI based medical tools, it provides an in-depth analysis of the current developments in relation to the area of medical diagnostics. The book focuses on how enterprises and institutes have developed their intellectual property portfolio, particularly patents, in this area. Cross-country patenting analysis helps in understanding key areas of growth in certain markets and also company strategies and arrangements. The introduction of AI based products in market is subject to regulation. The developments in

policy and regulation influence the development and deployment of such products into the market. This book brings focus to the development of policy and regulation and how regulatory developments impact the introduction of AI-based healthcare products from a cross-country perspective. Further, how regulatory developments lead to the evolution of standards, build reliability and safety in this area are also examined. The unique aspect of this book is the comprehensive coverage of the dual aspects of the nature and scope of AI-based innovations in health care and the related drug regulatory aspects which are imperative for the understanding for students, researchers, and those who work in this area.